Ultromics raises $55M Series C to scale AI-driven heart failure detection

Oxford-based Ultromics, a pioneer in AI-driven cardiology diagnostics solutions, has raised $55 million through its Series C funding round. 

Ultromics has developed the first FDA-cleared, Medicare-reimbursed AI technology designed to help clinicians detect Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis, two of the most difficult-to-diagnose forms of heart failure. Built on years of clinical research and analysis of hundreds of thousands of echocardiograms, the platform addresses a critical gap in cardiac care. 

Traditional methods often rely on subjective interpretation, leading to delayed or missed diagnoses. As many as 64 per cent of HFpEF cases go undiagnosed, while cardiac amyloidosis is frequently mistaken for more common heart conditions, leaving patients untreated until symptoms become severe or life-threatening.

Ultromics tackles this diagnostic gap with its EchoGo® platform, which uses AI to uncover hidden disease signals within standard echocardiograms, enabling earlier and more accurate detection of complex heart conditions. The solution integrates seamlessly into existing clinical workflows and requires no new hardware. 

Trained and validated on one of the world’s largest real-world echo datasets, EchoGo® provides real-time probability scores to help cardiologists identify high-risk patients sooner than traditional methods. 

Ross Upton, PhD, CEO and Founder, Ultromics, shared:

The reality is, hospitals already have the data, they just haven’t had the tools to extract diagnostic signals from it. By analysing routine echocardiograms with AI, we’re helping clinicians identify high-risk patients earlier, enabling intervention before the disease progresses. We’ve spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the US at a moment when health systems are actively looking to combat the growing heart failure crisis.

Ultromics has analysed over 430,000 echocardiograms to date. In clinical studies, its EchoGo® platform improved HFpEF detection by 73.6 per cent compared to standard risk scores. The company’s newest diagnostic model for cardiac amyloidosis, validated through a global study across 18 institutions, surpassed existing clinical risk scores and successfully distinguished the disease from similar cardiac conditions.

The funding round was co-led by L&G, Allegis Capital, and Lightrock, with continued backing from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. It also saw participation from two major US health systems, the University of Chicago Medicine and UPMC Enterprises, the innovation and investment arm of the University of Pittsburgh Medical Center.

Alastair Stewart, Head of Investments, Venture Capital, at L&G, commented: 

Ultromics has established itself as an early mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies. This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year.

With growing adoption and partnerships across flagship institutions, including the University of Chicago Medicine, University Hospitals Cleveland, Northwestern University, and Mayo Clinic, Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the USA’s Midwest. 

The platform is designed to assist hospitals by reducing unnecessary tests, streamlining workflows, and enabling earlier initiation of treatment. This approach aims to enhance the effectiveness of medical interventions while also reducing costs. 

Umur Hursever, Partner at Lightrock, emphasised the urgent need for scalable solutions that can improve early and accurate diagnosis of heart failure and cardiac amyloidosis, conditions that affect millions and place a heavy burden on healthcare systems. He noted that while new approaches hold promise for better patient outcomes, raising the standard of care remains a key priority, adding: 

Ultromics’ AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics’ mission and growing impact.

Ultromics has significantly advanced its platform and US market presence over the past year. In late 2024, it received FDA Breakthrough Device clearance for EchoGo® Amyloidosis, followed by the 2025 launch of EchoGo® Score to enhance HFpEF detection. With Medicare reimbursement now in place for both outpatient and inpatient use, the company is well-positioned for scaled adoption across U.S. hospitals.

Victor Westerlind, Managing Director at Allegis Capital, commented: 

There’s a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle, and echo images are hard to interpret. What’s exciting about Ultromics is how they’re closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it’s a diagnostic win that will help save lives.

Ultromics will use the funding to expand its presence in the US and other priority markets, targeting hospitals and echo labs that handle large volumes of at-risk patients. The goal is to make AI-powered diagnostics a standard part of cardiac assessments. 

The company is also growing its product pipeline to cover more cardiac conditions, broaden distribution channels, and strengthen collaborations with health systems and clinical experts.